-
PD-L1-Inhibitor bei Urothelkarzinom
-
Neuer oraler GnRH-Antagonist
-
The rapidly spreading variants share the spike N501Y substitution, which is of particular concern as it increases cell entry and receptor binding.

The ACTIV-2 trial will initially enrol 220 participants with mild or moderate COVID-19 who are at risk for disease progression.